Scarica l'app Stockscreener
118.84
0.56%
-0.67
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$119.51
Aprire:
$119.13
Volume 24 ore:
1.54M
Relative Volume:
0.96
Capitalizzazione di mercato:
$17.05B
Reddito:
$9.61B
Utile/perdita netta:
$1.62B
Rapporto P/E:
10.74
EPS:
11.07
Flusso di cassa netto:
$1.77B
1 W Prestazione:
+0.19%
1M Prestazione:
-14.60%
6M Prestazione:
-34.59%
1 anno Prestazione:
-41.30%
Intervallo 1D:
$117.14
$119.62
Intervallo di 1 settimana:
$115.44
$121.75
Portata 52W:
$110.03
$238.00
Biogen Inc Stock (BIIB) Company Profile
Nome
Biogen Inc
Settore
Industria
Telefono
(781) 464-2000
Indirizzo
225 BINNEY STREET, CAMBRIDGE, MA
Confronta BIIB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
118.84 | 17.05B | 9.61B | 1.62B | 1.77B | 11.07 |
|
LLY
Lilly Eli Co
|
884.54 | 794.47B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
154.58 | 370.90B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
186.06 | 301.01B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
62.08 | 258.93B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
112.14 | 218.33B | 51.72B | 11.94B | 13.81B | 5.88 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-04 | Downgrade | Argus | Buy → Hold |
| 2025-02-11 | Iniziato | Bernstein | Mkt Perform |
| 2025-01-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Downgrade | Stifel | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-09 | Downgrade | Jefferies | Buy → Hold |
| 2024-11-18 | Downgrade | Needham | Buy → Hold |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-31 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-14 | Reiterato | Needham | Buy |
| 2024-02-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2023-12-20 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-24 | Reiterato | UBS | Buy |
| 2023-05-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-04-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-10-13 | Aggiornamento | Stifel | Hold → Buy |
| 2022-10-07 | Aggiornamento | Argus | Hold → Buy |
| 2022-09-28 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Aggiornamento | Mizuho | Neutral → Buy |
| 2022-09-28 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Downgrade | Stifel | Buy → Hold |
| 2022-03-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Reiterato | Barclays | Equal Weight |
| 2022-02-04 | Reiterato | BofA Securities | Neutral |
| 2022-02-04 | Reiterato | Cowen | Outperform |
| 2022-02-04 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-04 | Reiterato | Needham | Buy |
| 2022-02-04 | Reiterato | Oppenheimer | Outperform |
| 2022-02-04 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Reiterato | Robert W. Baird | Neutral |
| 2022-02-04 | Reiterato | Wedbush | Neutral |
| 2022-02-04 | Reiterato | Wells Fargo | Equal Weight |
| 2022-02-04 | Reiterato | Wolfe Research | Peer Perform |
| 2022-01-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-01-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Ripresa | Raymond James | Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-06-18 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Reiterato | Truist | Buy |
| 2021-06-11 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-08 | Aggiornamento | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Reiterato | Barclays | Equal Weight |
| 2021-06-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-06-08 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-08 | Reiterato | Jefferies | Buy |
| 2021-06-08 | Reiterato | Morgan Stanley | Overweight |
| 2021-06-08 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Reiterato | Stifel | Buy |
| 2021-06-08 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-06-07 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Downgrade | DZ Bank | Buy → Hold |
| 2021-01-29 | Aggiornamento | Stifel | Hold → Buy |
| 2020-11-10 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-11-09 | Downgrade | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-11-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-04 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-11-04 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-07-27 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Downgrade | Citigroup | Neutral → Sell |
| 2020-04-23 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-01-27 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Downgrade | Robert W. Baird | Neutral → Underperform |
Mostra tutto
Biogen Inc Borsa (BIIB) Ultime notizie
Biogen (BIIB) to Release Quarterly Earnings on Thursday - MarketBeat
CANADA LIFE ASSURANCE Co Reduces Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Ossiam Buys 2,653 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Press Release Distribution & PR Platform - ACCESS Newswire
Envestnet Asset Management Inc. Reduces Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Cognitive Impairment Market Is Booming Worldwide 2025-2032 | Eisai Co., Biogen Inc., Novartis AG - openPR.com
Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent? (NASDAQ:BIIB) - Seeking Alpha
T. Rowe Price Investment Management Inc. Has $474.02 Million Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Pinebridge Investments L.P. Has $38.20 Million Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Amyotrophic Lateral Sclerosis (ALS) Market: Growth, Trends, - openPR.com
RBC Cuts Price Target on Biogen to $217 From $225, Keeps Outperform Rating - marketscreener.com
Commerce Bank Sells 2,830 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Royal Bank of Canada Forecasts Strong Price Appreciation for Biogen (NASDAQ:BIIB) Stock - MarketBeat
Spinal Muscular Atrophy Market Deep Research with Forecast, - openPR.com
Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline - Yahoo Finance
1 Safe-and-Steady Stock with Promising Prospects and 2 to Ignore - Yahoo Finance
Can Biogen Keep the Beat Streak Alive This Earnings Season? - TradingView
J. Safra Sarasin Holding AG Cuts Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Natixis Has $4.34 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
First Trust Advisors LP Increases Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen’s Friedreich’s ataxia treatment authorised in UK - Yahoo Finance
Biogen Inc. (NASDAQ:BIIB) Stock Holdings Lifted by Marshall Wace LLP - MarketBeat
Neurodegenerative Disease Market Key Players Analysis - openPR.com
Biogen Inc. (NASDAQ:BIIB) Stock Position Reduced by United Capital Financial Advisors LLC - MarketBeat
Biosimilars Market Expansion in 2025: The Next Big Thing - openPR.com
Biogen Obtains UK Marketing Clearance for Friedreich's Ataxia Treatment - marketscreener.com
Crohn's Disease Market Growth, Trends & Forecast 2025 | Top key - openPR.com
Wedbush Issues Positive Outlook for Biogen Earnings - MarketBeat
14 Analysts Have This To Say About Biogen - Benzinga
Erythromelalgia Treatment Market Overall Study Report - openPR.com
Inflammatory Bowel Disease Market Growth, Trends & Forecast 2025 | Top key playersPfizer Inc, Biogen, Novartis AG. - openPR.com
RBC Lifts Price Target on Biogen to $225 From $221, Keeps Outperform Rating - marketscreener.com
Townsquare Capital LLC Sells 9,997 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Wedbush Predicts Biogen's Q1 Earnings (NASDAQ:BIIB) - MarketBeat
Earnings Preview: What To Expect From Biogen's Report - MSN
Bleeding Disorders Treatment Market Set to Witness Significant - openPR.com
Biogen (NASDAQ:BIIB) shareholders have endured a 61% loss from investing in the stock five years ago - simplywall.st
Canada Pension Plan Investment Board Boosts Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Raymond James Financial Inc. Purchases Shares of 141,968 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
PEGylated Proteins Market Positioned for Accelerated Growth - openPR.com
Canada Post Corp Registered Pension Plan Acquires Shares of 9,718 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Sterling Capital Management LLC Has $1.32 Million Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Leerink Partnrs Has Bearish Estimate for Biogen Q2 Earnings - MarketBeat
Biogen/ Eisai win EU approval for Alzheimer’s therapy - MSN
Jump Financial LLC Grows Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc Azioni (BIIB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.28%
0.61%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):